Fujian Shengdi Pharmaceutical Co., Ltd.

This Phase 2 trial tests two experimental injections, HRS-7249 and SHR-1918, in 108 adults with severely high triglycerides who are at high risk of acute pancreatitis. The study aims to see if these drugs can safely lower fat levels in the blood and reduce the chance of a pancrea…

This Phase 2 trial tests an injectable drug called HRS-9563 in 234 adults with mild to moderate hypertension. Participants are randomly assigned to receive either the drug or a placebo injection. The main goal is to see if HRS-9563 can safely lower average blood pressure over 24 …

This study tests an investigational drug called HRS-7450 in 208 people who have had an acute ischemic stroke within the past 4.5 to 24 hours. Participants receive either a low, intermediate, or high dose of the drug or a placebo. The goal is to see if the drug helps improve recov…

This study tests an experimental injection called HRS-7249 in 224 adults with hyperlipidemia (high fat levels in the blood). The goal is to see if it safely lowers triglycerides, a type of blood fat linked to heart disease. Participants receive either the drug or a placebo, and r…

This study tests an experimental drug called HRS-5632 in 203 adults with high levels of lipoprotein(a), a fatty substance that raises the risk of heart attacks and strokes. Participants receive either the drug or a placebo to see if the drug safely lowers this substance. The goal…

This phase 3 study tests whether a new weekly injection called HRS9531 works better than semaglutide for weight loss in 572 adults with obesity. Participants receive either drug for 52 weeks, and researchers measure changes in body weight, waist size, and BMI. The trial is active…

This Phase 2 study tests an injectable drug called HRS9531 in 203 obese adults with a type of heart failure where the heart pumps normally but is stiff. Participants receive either the drug or a placebo for 52 weeks. The main goals are to see if the drug helps with weight loss an…

This Phase 1 trial investigates how the drug HRS-9057 is absorbed, processed, and eliminated in healthy men. Six participants receive a single dose, and researchers measure the drug and its breakdown products in blood, urine, and stool. The goal is to understand the drug's behavi…